Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXA-PSYCH
2022-501428-45-00Phase 3Authorised
- Sponsor
- Region Hovedstadens Psykiatri
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Dexamethasone arm with Placebo arm (2 arms). Primary endpoint: Change from baseline on MADRS-10 at day 7. Planned start Dec 2022; status: authorised.
02
Drugs
dexamethasone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2022-501428-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501428-45-00.